Filtered By:
Drug: Actos

This page shows you your search results in order of date.

Order by Relevance | Date

Total 156 results found since Jan 2013.

Rediscovery of pioglitazone
Orv Hetil. 2023 Jul 2;164(26):1012-1019. doi: 10.1556/650.2023.32783. Print 2023 Jul 2.ABSTRACTIn the past decade and a half, clinical diabetology has undergone enormous development. New drug classes have appeared in everyday practice (GLP1 receptor agonists, SGLT2 inhibitors), which are able to improve the outcome of cardiovascular (macrovascular) complications in diabetes within a few years or even a few months, in contrast to the drugs used in previous large, prospective studies (UKPDS, VADT). The use of thiazolidinediones (including pioglitazone) unfortunately and significantly has declined in recent years, both intern...
Source: Orvosi Hetilap - July 2, 2023 Category: General Medicine Authors: Bence Pokoly Anik ó Somogyi Source Type: research

Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Ischemic stroke patients with diabetes are at high risk for recurrent stroke and cardiovascular complications. Pioglitazone, a type of thiazolidinedione, has been shown to reduce cardiovascular complications i...
Source: Cardiovascular Diabetology - May 5, 2023 Category: Cardiology Authors: Joonsang Yoo, Jimin Jeon, Minyoul Baik and Jinkwon Kim Tags: Research Source Type: research

Pioglitazone Use Linked to Reduced Dementia Risk in T2DM
THURSDAY, Feb. 16, 2023 -- For patients with diabetes mellitus (DM), pioglitazone use is associated with a reduced risk for dementia, especially in those with a history of ischemic heart disease or stroke, according to a study published online Feb....
Source: - Pharma News - February 16, 2023 Category: Pharmaceuticals Source Type: news

Pioglitazone Use and Reduced Risk of Dementia in Patients With Diabetes Mellitus With a History of Ischemic Stroke
DISCUSSION: Pioglitazone use is associated with a lower risk of dementia in DM patients, particularly in those with a history of stroke or ischemic heart disease, suggesting the possibility of applying a personalized approach when choosing pioglitazone to suppress dementia in DM patients.PMID:36792375 | DOI:10.1212/WNL.0000000000207069
Source: Cancer Control - February 15, 2023 Category: Cancer & Oncology Authors: Junghee Ha Dong Woo Choi None Kim Keun You Kim Chung Mo Nam Eosu Kim Source Type: research

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack
CONCLUSIONS: Peroxisome proliferator-activated receptor gamma agonists probably reduce recurrent stroke and total events of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke, and may improve insulin sensitivity and the stabilisation of carotid plaques. Their effects on adverse events are uncertain. Our conclusions should be interpreted with caution considering the small number and the quality of the included studies. Further well-designed, double-blind RCTs with large samples are required to assess the efficacy and safety of PPAR-γ agonists in the secondary prevention of stroke and related vascular...
Source: Cochrane Database of Systematic Reviews - January 10, 2023 Category: General Medicine Authors: Jia Liu Lu-Ning Wang Source Type: research

Diabetes and Stroke: What Are the Connections?
J Stroke. 2023 Jan 3. doi: 10.5853/jos.2022.02306. Online ahead of print.ABSTRACTStroke is a major cause of death and long-term disability worldwide. Diabetes is associated with an increased risk of cardiovascular complications, including stroke. People with diabetes have a 1.5-2 times higher risk of stroke compared with people without diabetes, with risk increasing with diabetes duration. These risks may also differ according to sex, with a greater risk observed among women versus men. Several mechanisms associated with diabetes lead to stroke, including large artery atherosclerosis, cerebral small vessel disease, and car...
Source: Atherosclerosis - January 2, 2023 Category: Cardiology Authors: Ofri Mosenzon Alice Yy Cheng Alejandro A Rabinstein Simona Sacco Source Type: research

Identification of novel and potential PPAR γ stimulators as repurposed drugs for MCAO associated brain degeneration
Toxicol Appl Pharmacol. 2022 May 9:116055. doi: 10.1016/j.taap.2022.116055. Online ahead of print.ABSTRACTPeroxisome proliferator-activated receptor-gamma (PPARγ) has been shown to have therapeutic promise in the treatment of ischemic stroke and is supported by several studies. To identify possible PPARγ activators, the current study used an in silico technique in conjunction with molecular simulations and in vivo validation. FDA-approved drugs were evaluated using molecular docking to determine their affinity for PPARγ. The findings of molecular simulations support the repurposing of rabeprazole and ethambutol for the ...
Source: Toxicology and Applied Pharmacology - May 13, 2022 Category: Toxicology Authors: Halima Usman Zhen Tan Mehreen Gul Sajid Rashid Tahir Ali Fawad Ali Shah Shupeng Li Jing Bo Li Source Type: research

Activation of the PPAR γ Prevents Ferroptosis-Induced Neuronal Loss in Response to Intracerebral Hemorrhage Through Synergistic Actions With the Nrf2
Intracerebral hemorrhage (ICH) is a subtype of stroke characterized by high mortality and disability rates. The long-term effects of ICH-induced intracranial hematoma on patients’ neurological function are unclear. Currently, an effective treatment that significantly reduces the rates of death and disability in patients with ICH is not available. Based on accumulating evidence, ferroptosis may be the leading factor contributing to the neurological impairment caused by ICH injury. Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated receptor in the nuclear hormone receptor family that synergistical...
Source: Frontiers in Pharmacology - April 20, 2022 Category: Drugs & Pharmacology Source Type: research